Category: neuroendocrine tumors
Breaking News: US FDA Approves Lanreotide for Gastroenteropancreatic Neuroendocrine Tumors
December 16, 2014: The US Food and Drug Administration (FDA) today approved “lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic…
READ MORE
Carcinoid Cancer Foundation Awards Grant to Stanford University
The Carcinoid Cancer Foundation in White Plains, New York has awarded a grant of more than $65,000.00 to Stanford University in California to expand access to its Gallium-68 (Ga-68) DOTA-TATE PET/CT program for carcinoid and neuroendocrine tumor (NET)…
READ MORE
Zebra Talk — A Handbook for Newly Diagnosed Carcinoid & Neuroendocrine Tumor Patients and Their Primary Care Physicians
There’s a terrific new resource for carcinoid and neuroendocrine tumor patients and their primary care physicians entitled Zebra Talk. According to Suzi Garber of Bucks County, Pennsylvania, editor, the handbook “is intended as a reference for those…
READ MORE
NET Alliance Issues New E-Book on Neuroendocrine Cancer
NETrospectives, a new e-book produced by The NET Alliance, is “a journey through the past and a vision for the future of neuroendocrine cancer.” The e-book presents patients, patient advocates, and physicians talking about the diagnoses…
READ MORE
Carcinoid and Neuroendocrine Tumors in the News!
Who is at risk for getting carcinoid or another neuroendocrine cancer? What are the signs and symptoms? We are very pleased to share a feature article from the April 27, 2014 edition of the New York Daily News, “Daily Checkup: Carcinoid Tumors Have a Variety…
READ MORE
New England Carcinoid Connection Announces June 2014 Conference for the Carcinoid and Neuroendocrine Tumor Community
Carcinoid and neuroendocrine cancer patients, family members, caregivers, and healthcare professionals are invited to attend the New England Carcinoid Connection Conference on Friday, June 27, 2014 at The Lantana in Randolph, Massachusetts. The…
READ MORE
Neuroendocrine Tumors Featured in Society of Nuclear Medicine and Molecular Imaging 2014 Meeting
Josh Mailman, President of the NorCal CarciNET Community and Chair of the Patient Advocacy Advisory Board for the Society of Nuclear Medicine and Molecular Imaging (SNMMI), will give the Welcome presentation for the SNMMI Patient Education Day on June…
READ MORE
Gallium-68 Scan Coming to NOLANETS for Carcinoid and Neuroendocrine Tumor Patients
Dr. Eugene A. Woltering has announced that the Gallium-68 DOTATATE PET/CT scan is going to be available beginning in the summer of 2014 through The New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS) Neuroendocrine Tumor Program at …
READ MORE
Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!
The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for lunch on Sunday, May 4 from 12:30 to 3:30 pm in a private dining room at Dorrian’s restaurant in Manhattan…
READ MORE
Carcinoid and Neuroendocrine Tumor Specialist Dr. Eugene A. Woltering Named Chair of AJCC Expert Panel
Eugene A. Woltering, MD, The James D. Rives Professor of Surgery and Neuroscience and Director of Surgical Research at LSU Health Sciences Center/Ochsner in Kenner, Louisiana, has been selected to serve as Chair of the Neuroendocrine Tumors (NETs) …
READ MORE
Carcinoid Cancer Foundation (CCF)
Happy Father's Day!
